Adageis Secures $2M Seed Funding to Expand AI-Driven Healthcare Solutions

• Adageis closed a $2 million seed round at the end of Q4 2024 to support operational expansion, with the funding to enhance backend operations for next-generation software upgrades.
• Upgraded Electronic Health Record EHR”) connectivity will facilitate integration with over 90 EHR systems, while increased sales force investment will help accelerate growth and market adoption.
• Adageis’ AI-powered platform is designed to streamline healthcare operations, optimize provider revenue, and improve patient care outcomes.

Adageis, a forward-thinking healthcare technology company reshaping patient care through flexible AI-centric software solutions for healthcare organizations, has secured $2 million in seed financing to enhance its operations and expand its market reach. The funding, which closed at the end of Q4 2024, supports upgrades to the company’s backend infrastructure, allowing for next-generation improvements, expanded Electronic Health Record (“EHR”) system connectivity, and increased sales efforts to promote rapid growth.

With a unique offering in the healthcare space, the company’s ProActive Care Platform uses artificial intelligence to help healthcare providers shift from traditional fee-for-service models to value-based care. This transition enables organizations to reduce costs, improve patient care, and increase reimbursements by meeting key performance metrics.

A significant portion of the seed funding will be used to expand Adageis’ ability to connect with over 90 EHR systems. Seamless integration with widely used platforms like AthenaHealth, Cerner, eClinicalWorks, Allscripts, and Epic, will allow providers to implement Adageis’ technology without disrupting their workflows. The company’s flexible API enables smooth implementation and minimizes training time for healthcare professionals.

Adageis has rebranded its platform as a fintech AI solution, emphasizing its ability to simplify the complexities of insurance contracts. By doing so, providers can optimize revenue streams while ensuring high-quality patient care. The company’s technology helps healthcare organizations maximize reimbursements by aligning with value-based care metrics.

The company’s core offerings include:

• Value-Based Care Engine: A comprehensive platform designed to help healthcare organizations transition to value-based care, improving revenue while maintaining high standards of patient care.
• Patented Risk Engine (“PRE”): AI-driven analytics identify high-risk patients and care gaps, helping providers intervene earlier and reduce costs.
• Proactive Efficiency: The system continuously monitors patient health, enabling timely interventions beyond traditional office visits.
• Flexible Integration: Adageis’ technology is compatible with leading EHR systems, ensuring smooth implementation across various healthcare settings.

By leveraging AI, Adageis helps providers navigate complex insurance agreements, optimize patient care, and enhance operational efficiency. The expansion of its sales force will support the rapid adoption of its advanced technology in healthcare markets.

As value-based care continues to gain traction, Adageis’ AI-driven platform offers healthcare organizations a strategic tool to improve patient outcomes and financial performance. With its recent funding, the company is positioned to scale its impact in the evolving healthcare technology landscape.

For more information, visit the company’s website at www.Adageis.com.

NOTE TO INVESTORS: The latest news and updates relating to Adageis are available in the company’s newsroom at https://ibn.fm/Adageis

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN